Hycamtin Related Published Studies
Well-designed clinical trials related to Hycamtin (Topotecan)
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. [2008.01.15]
A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). [2007.09]
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. [2007.07]
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. [2007.05.20]
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. [2006.12.01]
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. [2006.10]
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. [2006.08.02]
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. [2006.06.20]
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. [2006.05.01]
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. [2006.04]
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. [2006.01]
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. [2005.10]
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. [2005.08.15]
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. [2005.08]
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. [2005.08]
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. [2005.07.20]
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. [2005.07.20]
Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). [2005.06]
Serum cystatin C is a better marker of topotecan clearance than serum creatinine. [2005.04.15]
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. [2004.10]
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. [2004.07.01]
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. [2004.01]
[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer] [2003.11]
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. [2003.08]
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. [2003.06]
Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. [2003.06]
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. [2003.03.15]
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. [2003.03.01]
A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. [2002.10]
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. [2002.07.01]
Urinary and fecal excretion of topotecan in patients with malignant solid tumours. [2002.07]
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. [2002.05]
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. [2002.01]
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. [2001.12.15]
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. [2001.07.15]
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. [2001.04.15]
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. [2001.04.01]
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. [2001.04.01]
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. [2001.03.15]
Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. [2000.06]
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. [2000.05]
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. [2000.05]
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan. [2000]
[Topotecan: prospects for using it in combination therapy for ovarian carcinoma] [1999.11]
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. [1999.09]
Oral topotecan: bioavailablity and effect of food co-administration. [1999.07]
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. [1999.02]
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. [1999]
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. [1998.06]
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. [1997.06]
Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. [1995.10]
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. [1995.10]
Well-designed clinical trials possibly related to Hycamtin (Topotecan)
Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. [2007.11]
Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. [2007.06.01]
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. [2006.03]
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. [2006.01.07]
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. [2005.03.20]
Second-line chemotherapy for non-small cell lung cancer. [2003.08]
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. [2003.08]
Combined-modality therapy of locally advanced cervical cancer. [2003.05.15]
[Developed new agents for lung cancer] [2002.02]
Evaluation of radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. [2000.07]
Other research related to Hycamtin (Topotecan)
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402. [2008.10.14]
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. [2008.10]
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. [2008.08.01]
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. [2008.08]
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. [2008.08]
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. [2008.07.01]
Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. [2008.07]
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. [2008.06]
Prolonged survival with continuous infusion topotecan: a report of 2 cases. [2008.06]
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. [2008.05.01]
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. [2008.05]
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. [2008.05]
The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. [2008.04.02]
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. [2008.04]
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. [2008.04]
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. [2008.04]
A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. [2008.03]
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. [2008.03]
Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. [2008.02]
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. [2008.02]
Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain. [2008.02]
A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan. [2008.02]
Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. [2008.01.01]
Weekly topotecan for recurrent platinum resistant ovarian cancer. [2008.01]
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. [2008.01]
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. [2008.01]
Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. [2008.01]
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. [2007.12.20]
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. [2007.11.30]
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. [2007.11.22]
Population pharmacokinetic analysis of topotecan in pediatric cancer patients. [2007.11.15]
Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). [2007.11]
Topotecan in cervical cancer. [2007.11]
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. [2007.11]
Recent advances with topotecan in the treatment of lung cancer. [2007.10]
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. [2007.10]
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer] [2007.10]
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. [2007.09]
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. [2007.09]
|
